Switch theme
Sign up to access all valuation multiples
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
2007
2
LTM Revenue $1.0M
Last FY EBITDA -$5.6M
$5.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Addex Therapeutics has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Addex Therapeutics achieved revenue of $0.5M and an EBITDA of -$5.6M.
Addex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Addex Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$5.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1150% | XXX | XXX | XXX |
| EBIT | -$3.7M | XXX | -$3.3M | XXX | XXX | XXX |
| EBIT Margin | -361% | XXX | -682% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | $8.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | 1746% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Addex Therapeutics's stock price is CHF 0 (or $0).
Addex Therapeutics has current market cap of CHF 7.6M (or $9.1M), and EV of CHF 4.3M (or $5.1M).
See Addex Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.1M | $9.1M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Addex Therapeutics has market cap of $9.1M and EV of $5.1M.
Addex Therapeutics's trades at 10.5x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Addex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Addex Therapeutics's P/E ratio is not available.
See valuation multiples for Addex Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.1M | XXX | $9.1M | XXX | XXX | XXX |
| EV (current) | $5.1M | XXX | $5.1M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAddex Therapeutics's last 12 month revenue growth is 75%
Addex Therapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.9M for the same period.
Addex Therapeutics's rule of 40 is -559% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Addex Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Addex Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 75% | XXX | 93% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1150% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -559% | XXX | -1074% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 108% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 782% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Addex Therapeutics acquired XXX companies to date.
Last acquisition by Addex Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Addex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Addex Therapeutics founded? | Addex Therapeutics was founded in 2007. |
| Where is Addex Therapeutics headquartered? | Addex Therapeutics is headquartered in Switzerland. |
| How many employees does Addex Therapeutics have? | As of today, Addex Therapeutics has 2 employees. |
| Who is the CEO of Addex Therapeutics? | Addex Therapeutics's CEO is Mr. Tim Dyer. |
| Is Addex Therapeutics publicy listed? | Yes, Addex Therapeutics is a public company listed on SWX. |
| What is the stock symbol of Addex Therapeutics? | Addex Therapeutics trades under ADXN ticker. |
| When did Addex Therapeutics go public? | Addex Therapeutics went public in 2007. |
| Who are competitors of Addex Therapeutics? | Similar companies to Addex Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Addex Therapeutics? | Addex Therapeutics's current market cap is $9.1M |
| What is the current revenue of Addex Therapeutics? | Addex Therapeutics's last 12 months revenue is $1.0M. |
| What is the current revenue growth of Addex Therapeutics? | Addex Therapeutics revenue growth (NTM/LTM) is 75%. |
| What is the current EV/Revenue multiple of Addex Therapeutics? | Current revenue multiple of Addex Therapeutics is 5.0x. |
| Is Addex Therapeutics profitable? | Yes, Addex Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
